<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82708">
  <stage>Registered</stage>
  <submitdate>31/03/2008</submitdate>
  <approvaldate>10/04/2008</approvaldate>
  <actrnumber>ACTRN12608000184370</actrnumber>
  <trial_identification>
    <studytitle>Auto positive airway pressure for obstructive sleep apnoea</studytitle>
    <scientifictitle>Auto PAP: its effectiveness in reducing the apnoea hypopnoea index in severe obstructive sleep apnoea</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Severe Obstructive Sleep Apnoea</healthcondition>
    <healthcondition>Obstructive sleep apnoea</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Sleep apnoea</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Crossover trial of AutoPAP and CPAP for a period of 4 nights with a 4 night washout</interventions>
    <comparator>Continuous Positive Airway Pressure (CPAP) for 4 nights</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Apnoea Hypopnoea Index (events per hour) on treatment after 4 nights lead in</outcome>
      <timepoint>Each treatment will be used for 4 nights with the 4th night spent at the laboratory for monitoring and recording of end points</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Augmentation index (measure of arterial stiffness) measured at the start and end of each treatment arm</outcome>
      <timepoint>Start end end of each arm- 4 nights</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with severe OSA and either BMI &gt; 40kg/m2 or neck circumference&gt; 48cm plus a need for a manually titrated CPAP pressure of &gt;= 14cmH2O to prevent 95% of OSA</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Another sleep disorder
Cardiac or respiratory failure
Poor comprehension of English</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Subjects enrolled by Medical Director who ensures inclusion criteria met.  They are not involved in randomisation.  Randomisation is in an opaque envelope opened by the technician providing treatment</concealment>
    <sequence>Coin toss determines order of randomisation.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/03/2008</anticipatedstartdate>
    <actualstartdate>15/03/2008</actualstartdate>
    <anticipatedenddate>1/09/2008</anticipatedenddate>
    <actualenddate>1/11/2008</actualenddate>
    <samplesize>12</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Otago</primarysponsorname>
    <primarysponsoraddress>PO Box 56
DUNEDIN
Leith St Dunedin</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Asthma and Respiratory Foundation of NZ</fundingname>
      <fundingaddress>PO Box 1459
Wellington
22 Panama St Wellington</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Asthma and Respiratory Foundation of NZ</fundingname>
      <fundingaddress>PO Box 1459
Wellington</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>Research Administrator</sponsorname>
      <sponsoraddress>Otago University Wellington
PO Box 7343
Wellington South
Mein St Newtown Wellington</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Study aims to determine whether autoPAP technology is suitable for patients requiring a high treatment pressure to treat obstructive sleep apnoea.  The study found that this was very variable with some patients being well treated and others not.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Central Regional Ethics Committee</ethicname>
      <ethicaddress>PO Box 5013
Wellington</ethicaddress>
      <ethicapprovaldate>14/09/2007</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>1/09/2007</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Central Regional Ethics Committee</ethicname>
      <ethicaddress>PO Box 5013
Wellington</ethicaddress>
      <ethicapprovaldate>14/09/2007</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>1/09/2007</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Alister Neill</name>
      <address>Department of Medicine
OUW
PO Box 7343
Wellington South</address>
      <phone>+64 4 3855999</phone>
      <fax />
      <email>alister.neill@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Alister Neill</name>
      <address>Department of Medicine
OUW
PO Box 7343
Wellington South</address>
      <phone>+64 4 3855999</phone>
      <fax />
      <email>alister.neill@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Angela Campbell</name>
      <address>Dept Medicine
OUW
PO Box 7343
Wellington South</address>
      <phone>+64 4 9208819</phone>
      <fax />
      <email>wellsleep@paradise.net.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Alister Neill</name>
      <address>Dept Medicine
University Otago Wellington
PO Box 7343
Wellington NZ</address>
      <phone>+64 4 3855999</phone>
      <fax />
      <email>alister.neill@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>